Drug Profile
BOS 1728515
Alternative Names: BOS-1728515; F17727Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer Boston Pharmaceuticals; Pierre Fabre
- Class Antiarrhythmics; Small molecules
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atrial fibrillation